Increased incidence of obstetric complications in women carrying mitochondrial DNA mutations: a retrospective cohort study in a single tertiary centre.
Mitochondrial disease
OXPHOS mutations
pregnancy complications
Journal
BJOG : an international journal of obstetrics and gynaecology
ISSN: 1471-0528
Titre abrégé: BJOG
Pays: England
ID NLM: 100935741
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
accepted:
20
09
2018
pubmed:
22
11
2018
medline:
24
9
2019
entrez:
22
11
2018
Statut:
ppublish
Résumé
To investigate the obstetric outcome of women carriers of the oxidative phosphorylation (OXPHOS) disorder mutation. A retrospective cohort study in a single tertiary centre. A review of the obstetric history of women referred for prenatal screening of a mitochondrial disorder was performed. Women were divided into three groups: (1) women carrying mitochondrial DNA (mtDNA) mutations; (2) healthy women with a family history of mtDNA-related OXPHOS disorder; and (3) healthy women carrying heterozygote nuclear DNA mutations. Obstetric history and pregnancy complications were evaluated separately in the three groups and compared with the control group. MAIN OUTCOME MEASURES PREGNANCY COMPLICATIONS. Seventy-five women were included with 287 cumulative pregnancies. Groups 1 and 3 had a significantly greater proportion of terminations of pregnancy (20 and 13% versus 0.8%, P < 0.001), and a lower percentage of live births (52 and 72% versus 87%, P = 0.001), compared with controls. Apart from this, the rate of obstetric complications in group 3 did not differ from the controls. The obstetric history of women in group 1 was marked by higher rates of early miscarriages (26 versus 11%, P = 0.004), gestational diabetes (14 versus 3%, P = 0.02), intrauterine growth restriction (IUGR, 10 versus 1%, P = 0.008), and postpartum haemorrhage than were reported for controls (12 versus 2%, P = 0.01). Women who are heteroplasmic for OXPHOS mutations have a higher incidence of pregnancy losses, gestational diabetes, IUGR, and post postpartum haemorrhage. Women heteroplasmic for mitochondrial DNA mutations have a higher incidence of obstetric complications, compared with the control group.
Identifiants
pubmed: 30461153
doi: 10.1111/1471-0528.15515
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1372-1379Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2018 Royal College of Obstetricians and Gynaecologists.
Références
Thorburn DR. Mitochondrial disorders: prevalence, myths and advances. J Inherit Metab Dis 2004;27:349-62.
Suomalainen A. Biomarkers for mitochondrial respiratory chain disorders. J Inherit Metab Dis 2011;34:277-82.
Munnich A, Rustin P. Clinical spectrum and diagnosis of mitochondrial disorders. Am J Med Genet 2001;106:4-17.
von Kleist-Retzow J-C, Cormier-Daire V, Viot G, Goldenberg A, Mardach B, Amiel J, et al. Antenatal manifestations of mitochondrial respiratory chain deficiency. J Pediatr 2003;143:208-12.
Holt IJ, Cooper JM, Morgan-Hughes JA, Harding AE. Deletions of muscle mitochondrial DNA. Lancet 1988;1:1462.
Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990;46:428-33.
Monnot S, Gigarel N, Samuels DC, Burlet P, Hesters L, Frydman N, et al. Segregation of mtDNA throughout human embryofetal development: m.3243A>G as a model system. Hum Mutat 2011;32:116-25.
Steffann J, Frydman N, Gigarel N, Burlet P, Ray PF, Fanchin R, et al. Analysis of mtDNA variant segregation during early human embryonic development: a tool for successful NARP preimplantation diagnosis. J Med Genet 2006;43:244-7.
Annaiah TK, Kodakkattil S, Sriemevan A. Pregnancy with mitochondrial encephalopathy lactic acidosis and stroke-like episodes (MELAS syndrome) leading to confusion in the diagnosis of pulmonary embolism. J Obstet Gynaecol 2007;27:618-9.
Moriarty KT, McFarland R, Whittaker R, Burch J, Turnbull HE, Taylor RW, et al. Pre-eclampsia and magnesium toxicity with therapeutic plasma level in a woman with m.3243A>G melas mutation. J Obstet Gynaecol 2008;28:349.
de Laat P, Fleuren LHJ, Bekker MN, Smeitink JAM, Janssen MCH. Obstetric complications in carriers of the m.3243A>G mutation, a retrospective cohort study on maternal and fetal outcome. Mitochondrion 2015;25:98-103.
Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, Nygren K, et al. International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009. Fertil Steril 2009;92:1520-4.
Salomon LJ, Bernard JP, Ville Y. Estimation of fetal weight: reference range at 20-36 weeks’ gestation and comparison with actual birth-weight reference range. Ultrasound Obstet Gynecol 2007;29:550-5.
Lubchenco LO, Hansman C, Dressler M, Boyd E. Intrauterine growth as estimated from liveborn birth-weight data at 24 to 42 weeks of gestation. Pediatrics 1963;32:793-800.
Chang TC, Robson SC, Boys RJ, Spencer JA. Prediction of the small for gestational age infant: which ultrasonic measurement is best? Obstet Gynecol 1992;80:1030-8.
Haute Autorité de Santé - Suivi et orientation des femmes enceintes en fonction des situations à risque identifiées [Internet]. [www.has-sante.fr/portail/jcms/c_547976/fr/suivi-et-orientation-des-femmes-enceintes-en-fonction-des-situations-a-risque-identifiees]. Accessed May 2016.
Shi Z, Long W, Zhao C, Guo X, Shen R, Ding H. Comparative proteomics analysis suggests that placental mitochondria are involved in the development of pre-eclampsia. PLoS One 2013;8:e64351.
Tay SKH, Shanske S, Kaplan P, DiMauro S. Association of mutations in SCO2, a cytochrome c oxidase assembly gene, with early fetal lethality. Arch Neurol 2004;61:950-2.
Metzger BE. Summary and recommendations of the Third International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes 1991;40 (Suppl 2):197-201.
Damm P, Vestergaard H, Kühl C, Pedersen O. Impaired insulin-stimulated nonoxidative glucose metabolism in glucose-tolerant women with previous gestational diabetes. Am J Obstet Gynecol 1996;174:722-9.
Kautzky-Willer A, Prager R, Waldhausl W, Pacini G, Thomaseth K, Wagner OF, et al. Pronounced insulin resistance and inadequate beta-cell secretion characterize lean gestational diabetes during and after pregnancy. Diabetes Care 1997;20:1717-23.
Chinnery PF. Mitochondrial disorders overview. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJ, et al., éditeurs. GeneReviews(®) [Internet]. Seattle, WA: University of Washington, Seattle; 1993 [www.ncbi.nlm.nih.gov/books/NBK1224/]. Cité 14 November 2016.
de Laat P, Koene S, van den Heuvel LPWJ, Rodenburg RJT, Janssen MCH, Smeitink JAM. Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A > G mutation. J Inherit Metab Dis 2012;35:1059-69.